Guizhou Sanli Pharmaceutical Co Ltd (603439) - Total Liabilities

Latest as of September 2025: CN¥1.30 Billion CNY ≈ $190.23 Million USD

Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has total liabilities worth CN¥1.30 Billion CNY (≈ $190.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Guizhou Sanli Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)

This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 603439 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Guizhou Sanli Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Corvus Pharmaceuticals Inc NASDAQ:CRVS	USA	$12.52 Million
Guangzhou Hongli Opto Electron SHE:300219	China	CN¥3.36 Billion
G R Infraprojects Limited NSE:GRINFRA	India	Rs66.57 Billion
Gr. Sarantis S.A. AT:SAR	Greece	€232.08 Million
PC Jeweller Limited NSE:PCJEWELLER	India	Rs16.77 Billion
Wuhan LinControl Automotive Electronics Co. Ltd. A SHG:688667	China	CN¥386.49 Million
Dividend 15 Split Corp TO:DFN	Canada	CA$1.46 Billion
Nova Technology TWO:6613	Taiwan	NT$4.64 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Guizhou Sanli Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Guizhou Sanli Pharmaceutical Co Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.45	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.88	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.46	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Guizhou Sanli Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual total liabilities of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.60 Billion ≈ $233.76 Million	+31.90%
2023-12-31	CN¥1.21 Billion ≈ $177.22 Million	+109.39%
2022-12-31	CN¥578.40 Million ≈ $84.64 Million	+55.10%
2021-12-31	CN¥372.93 Million ≈ $54.57 Million	+34.67%
2020-12-31	CN¥276.91 Million ≈ $40.52 Million	+247.35%
2019-12-31	CN¥79.72 Million ≈ $11.67 Million	+35.84%
2018-12-31	CN¥58.69 Million ≈ $8.59 Million	-36.26%
2017-12-31	CN¥92.07 Million ≈ $13.47 Million	+5.30%
2016-12-31	CN¥87.44 Million ≈ $12.79 Million	+1.50%
2015-12-31	CN¥86.14 Million ≈ $12.60 Million	-38.33%
2014-12-31	CN¥139.67 Million ≈ $20.44 Million	+7.01%
2013-12-31	CN¥130.52 Million ≈ $19.10 Million	--

About Guizhou Sanli Pharmaceutical Co Ltd

SHG:603439 China Drug Manufacturers - Specialty & Generic

Market Cap

$935.89 Million

CN¥6.40 Billion CNY

Market Cap Rank

#9347 Global

#2409 in China

Share Price

CN¥15.64

Change (1 day)

+3.30%

52-Week Range

CN¥10.49 - CN¥17.00

All Time High

CN¥41.67